American Association for Cancer Research: Adding Immunotherapy to Neoadjuvant Chemoradiation May Improve Outcomes in Esophageal Cancer
November 16, 2024
November 16, 2024
PHILADELPHIA, Pennsylvania, Nov. 16 (TNSres) -- The American Association for Cancer Research issued the following news release:
* * *
Combination of radiation, chemotherapy, and immunotherapy can shrink tumors and allow surgery, with much better survival rate rather than with non-surgical treatment alone
* * *
In patients with unresectable, locally advanced esophageal cancer, the triple combination of radiation, chemotherapy, and immunotherapy . . .
* * *
Combination of radiation, chemotherapy, and immunotherapy can shrink tumors and allow surgery, with much better survival rate rather than with non-surgical treatment alone
* * *
In patients with unresectable, locally advanced esophageal cancer, the triple combination of radiation, chemotherapy, and immunotherapy . . .